Programmed Death Ligand 1 (PD-L1) positivity in metastatic sites in the Foundation Medicine (FM) database and in the IMpassion-130 data2
| Sample type | FM total N(%) | FM N PD-L1+ (%) | IMpassion-130 total N(%) | IMpassion-130 N PD-L1+ (%) |
| Primary tumor | 179 (52.6) | 114 (63.7) | 559 (62) | 246 (44) |
| Metastatic lesion | 161 (47.4) | 68 (42.2) | 342 (38) | 123 (36) |
| Sites of metastases | N (% of metastatic samples) | N PD-L1+ (%) | IMpassion-130 N (% of metastatic samples) | IMpassion-130 N PD-L1+ (%) |
| Lung | 16 (10.0) | 11 (68.8) | 54 (15.8) | 23 (43) |
| Soft issues | 23 (14.3) | 15 (65.2) | 36 (10.5) | 11 (30) |
| Lymph nodes | 45 (28.0) | 23 (51.1) | 108 (31.6) | 55 (51) |
| Skin | 21 (13.0) | 5 (23.8) | 18 (5.3) | 9 (48) |
| Liver | 23 (14.3) | 4 (17.4) | 45 (13.2) | 6 (13) |